Nov 11, 2025 · 2h 6m · cheeky-pint
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Dave Ricks · 1h 25m spoken Patrick Collison · 14m spoken John Collison · 11m spoken Paul Janssen · 47s spoken Archive Footage · 3s spoken
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Eli Lilly CEO Dave Ricks joins John and Patrick Collison to discuss the science and scaling of GLP-1 therapies, direct-to-consumer pharmaceutical distribution, and the capital allocation strategies driving modern drug discovery.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. John holds 9.4% of the talking time here. How this is scored →
John as informed peer 5.6 Guest teaching 6.8 Guest disagreement 2.1 John pushing back 2.3
speaking balance: gold is John, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 25:34 Direct rejection of host premise on obesity reimbursement
Dave Ricks immediately pushes back against John's assertion that GLP-1s lack near-term economic returns by citing independent ICER data proving a two-year break-even.
Hardest push from John ▶ 3:39 Patrick pressing with Derek Lowe's skepticism on AI drug discoveryPatrick challenges the prevailing AI enthusiasm in pharma by confronting Ricks with Derek Lowe's critique on target selection and human toxicity failures.
Biggest teaching moment ▶ 1:23:55 Reframing GLP-1 discovery from accidental finding to decades of incretin researchRicks corrects John's misconception that weight loss was an accidental side-effect, breaking down the 50-year history of incretin biology and peptide stabilization.
John holds their own ▶ 1:50:30 John analyzing Eli Lilly's PE valuation disparity against the sectorJohn demonstrates sharp financial command by highlighting Lilly's 50x PE ratio compared to the broader pharma sector's 12x multiple to drill into market confidence.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | John as informed peer | Guest teaching | Guest disagreement | John pushing back | Why |
|---|---|---|---|---|---|---|
| Eli Lilly's Supercomputing Initiative and AI in Drug Discovery | 6 | 5 | 2 | 2 | Patrick probes Dave Ricks by citing Derek Lowe's skepticism regarding AI's utility in target selection and human toxicity prediction. Ricks acknowledges the limitation, explaining that AI drug discovery is constrained by knowing only a fraction of human biology. | |
| Science-Driven Capital Allocation and Executive Decision-Making | 5 | 6 | 1 | 1 | John and Patrick ask how a non-scientist CEO navigates billion-dollar capital allocation choices in Phase 3 trials. Ricks details his autodidactic routines with LLMs, scientific journals, and Lilly's institutional decision bumpers. | |
| Clinical Trial Cost Drivers and Decentralized Enrollment | 6 | 7 | 2 | 3 | Patrick challenges the exorbitant 40,000 dollar per enrollee trial cost and proposes a direct-to-patient mail model. Ricks schools the hosts on clinical trial mechanics, institutional overhead markups, and trial comparisons between the US and Europe. | |
| Regulatory Ratchets, Historical Safety Crises, and Institutional Inertia | 6 | 7 | 3 | 3 | The hosts invoke Paul Janssen's critique of regulatory bureaucracy. Ricks provides detailed context around historical safety scares like Vioxx and Avandia, demonstrating how regulatory ratchets permanently add trial burdens. | |
| Metabolic Biology, Obesity Economics, and Caloric Regulation | 5 | 8 | 4 | 3 | John asserts that weight loss reimbursement fails due to long payoff horizons, but Ricks rejects the premise by citing ICER data showing a two-year break-even. Ricks then explains the evolutionary biology of human hunger set points and hyperinsulinemia. | |
| Reimagining Pricing Models for Curative and Genetic Therapies | 6 | 6 | 1 | 2 | Patrick contrasts recurring therapy revenue against one-time curative gene therapies using a SaaS vs shrink-wrap software metaphor. Ricks agrees and proposes novel annuity and licensing reimbursement models with built-in warranties. | |
| Pharmaceutical Incentive Structures, Patent Durations, and Market Distortions | 6 | 7 | 2 | 3 | The conversation examines how shortened effective patent lives and IRA price controls depress biotech capital formation. Ricks details how generic cliff economics wipe out 97 percent of drug value and discusses value-based pricing mechanisms. | |
| Global Pricing Disparities, PBM Rebates, and the Insulin Overhaul | 6 | 8 | 3 | 4 | John raises US-international price disparities and the public backlash over insulin pricing. Ricks exposes PBM gross-to-net spread arbitrage and explains how launching an authorized generic bypassed pharmacy formulary resistance. | |
| US Healthcare Inefficiencies, Opaque Costs, and Direct Consumerism | 5 | 7 | 2 | 2 | John highlights the absurdity of opaque hospital pricing and the cultural peculiarity of direct-to-consumer pharma advertising. Ricks shares personal anecdotes illustrating site-of-care fee distortion and outlines a vision for consumer-driven preventative care. | |
| Structuring Innovation: Biotech Agility versus Big Pharma Scale | 5 | 7 | 2 | 2 | Patrick questions whether big pharma is turning into private equity portfolio management as biotechs drive two-thirds of new approvals. Ricks differentiates between early discovery agility and downstream scale in trials and manufacturing. | |
| Mid-Roll Sponsor: Stripe Enterprise Direct-to-Consumer Infrastructure | 6 | 7 | 3 | 3 | Following an ad read, Patrick and Dave debate the rise of China's share in the global drug pipeline from near zero to 30 percent. Ricks highlights national security concerns and proposes expanding small-molecule data exclusivity to counter shadow generics. | |
| Generic Drug Quality Control, Bioequivalence, and Manufacturing Resilience | 6 | 7 | 2 | 2 | Patrick probes the quality assurance, bioequivalence standards, and offshore manufacturing risks of generic medications. Ricks explains pharmacokinetic bioequivalence margins, excipient differences, and supply chain vulnerabilities. | |
| Unlocking GLP-1 Mechanisms: Inflammation, Neurobiology, and Systemic Health | 5 | 8 | 3 | 2 | John suggests weight loss discovery was accidental, but Ricks corrects him with the 50-year history of incretin research starting from Gila monster saliva. Ricks then explains systemic inflammation drops and neurobiological dopamine signaling pathways. | |
| Scaling GLP-1 Delivery: Oral Formulations, Advertising, and Compounding Hazards | 5 | 7 | 3 | 2 | Patrick raises the prevalence of gray-market research peptides in tech circles. Ricks delivers an uncompromising warning about unapproved Chinese peptides and compounding pharmacy risks, contrasting them with oral small-molecule GLP-1 scaling. | |
| LillyDirect: Disintermediating Supply Chains with Digital Health Platforms | 6 | 6 | 1 | 2 | John and Patrick discuss LillyDirect's digital model disintermediating traditional pharmacy channels. Ricks recounts the strategic pushback from legacy pharmacy chains and how direct billing platforms unlock massive scale. | |
| Eli Lilly's Market Leadership, Growth Velocity, and Capital Discipline | 6 | 6 | 2 | 2 | John quizzes Ricks on Eli Lilly's 50x forward valuation multiple and rapid 40 percent growth relative to peers. Ricks articulates Lilly's R&D productivity premium, short cycle times, and focus on zero-dollar market Moonshots. | |
| Scaling R&D Investment: Gateway Labs and Multimodal Discovery Platforms | 5 | 7 | 1 | 2 | Patrick asks if booming GLP-1 revenues will cross-subsidize broad biomedical discovery. Ricks discusses scaling R&D toward nation-state levels, managing Gateway Labs incubators, and maintaining discipline against overpaying for external assets. | |
| Enduring Corporate Culture, Talent Rotation, and Leadership Succession | 5 | 6 | 1 | 2 | John asks how Lilly's 150-year longevity informs talent development and executive succession. Ricks describes internal cross-functional rotations, keeping non-manufacturing headcount flat, and balancing internal culture with outside executive hires. |
Statements from this episode (53)
Ricks: Eli Lilly is building pharma's largest biological supercomputer
“Building a supercomputer on our, on-prem for us, really just to run proprietary drug discovery models. We think it's the biggest biologically focused supercomputer there is. And certainly the biggest pharma's done. Yes. With B 300 latest chipset.”
Ricks: Machine-designed drugs haven't reached clinical trials yet, but are coming
“I don't know of one that's come through the machine driven discovery process, which is really machine plus human that's made it to the clinic yet, but they're coming.”
Ricks: AI won't solve biology until we understand over 50% of it
“And today, I don't know, I would estimate we might know 10 to 15% of human biology. So the machine's not going to be good at all until we get way above 50%.”
Ricks: Claude and xAI beat ChatGPT for science because references check out
“I don't use that one for science actually. It's too, too horrible.
Patrick Collison: So which one do you use for science?
Dave Ricks: I tend to use either Claude or the XAI one. I find it more terse. And more, the references actually check out more often.”
Ricks: Lilly executives have a rule to never decide in one meeting
“We actually have a rule to like never decide in one meeting.”
Ricks: Lilly will spend nearly 25% of revenue on R&D this year
“We'll spend almost 25% of sales this year.
John Collison: I liked your way of putting us that you spend more on medical R&D than Germany does.
Dave Ricks: Yes.
Dave Ricks: Yeah.
Dave Ricks: We're at the nation state level. It'll be, you know, fourteen billion …”
Ricks: Developing a drug costs $4B, with over 60% spent in Phase 3
“The final stage of testing, the average drug costs three and a half, four billion to make more than 60% of that is the last step.”
Collison: Median clinical trial enrollment costs $40,000 per patient
“The median clinical trial enrollee, it now costs 40,000 dollars.”
Ricks: Lilly's industry-leading R&D ROI comes from process, not picking winners
“I think one of the reasons Lilly has probably the highest return on investment in R&D in the industry is because not the picking of winners and losers, but the, actually the process by which we run it.”
Ricks: US cancer trial enrollment is 4% versus over 25% in Spain
“Only four percent of patients who have cancer in the US are in clinical trials, whereas in Spain and Australia, it's over 25%.”
Ricks: Lilly develops clinical drugs in under 7 years versus industry average
“Drug development time in the industry, It's about 10 years in the clinic, a little less right now. We're running a little less than seven at Lilly”
Ricks: There are roughly 2,000 approved synthetic medicines across 400 mechanisms
“We probably have 2000 manmade approved medicines versus natural products or vitamins or other things, and maybe 400 unique mechanisms.”
Ricks: Cardiovascular trial rules added five years to diabetes drug development
“The Evandia one, we know well, we work in diabetes, actually caused a policy change, and the policy change was you must rule out cardiovascular risk prior to market entry, and as you may know some conditions like diabetes have a more continuous variable you're…”
Ricks: Expensive cardiovascular trial mandates protect GLP-1 incumbents from low-cost competition
“Now, by happy accident, we are all now really pleased with, like, incretins, like our trisepetide to run them because they frequently demonstrate massive benefit. Uncardiovascular. And in some ways, it creates a barrier to entry for the next low-cost Chinese p…”
Ricks: ICER found tirzepatide and semaglutide cost-effective at current pricing
“They just analyzed our medicines, trisepatide and semaglutide, and they said, actually, they're both cost effective at current pricing. In fact, Zepbound or Trisepatide was, the threshold they have is to save a 100,000 dollars per person per year in downstream…”
Ricks: Current GLP-1 drug pricing will fall amid competition and pressure
“And the current pricing isn't going to stay. Let's be honest. There'll be more competition. The government wants to lower our prices.”
Ricks: Tirzepatide would be universally reimbursed if introduced in 1972
“If the first medicine we had to treat metabolic conditions was terzepatide in 1972, I have no doubt it would be reimbursed everywhere and broadly used in the system.”
Ricks: Eli Lilly is developing a one-time PCSK9 gene editing medicine
“We have a medicine development that will Knock down your LDL, if it's safe enough, and then one undone, PCSK nine edit in your liver, and presumably that will last the rest of your life, and your LDLs will be between 20 and 40 forever.”
Ricks: Lilly is considering SaaS-style recurring pricing for common gene therapies
“It's conceivable that one could create like a licensing concept, stealing from the SAS model, where you say, we'll do the procedure for free. And as long as it's working for you will deposit X amount in our bank account, and you're getting the value, and we're…”
Ricks: Medicine accounts for only 10 cents of every US healthcare dollar
“In the US, the most expensive healthcare system in the world, we spend 10 cents on the dollar on medicine. The other 90 cents go through everything else that medicine's trying to prevent.”
Ricks: Non-Lilly large pharma multiples are at a 20-year low
“If you look at the large cap farmers, not Lilly, but the other ones, the multiples, the most compressed it's been in 20 years. If you look at biotech, the XBI, I think half of the XBI is trading below cash. And then if you look at. Venture. Half of the rounds …”
Ricks: Around 80 GLP-1 drug candidates are in clinical pipelines globally
“We only have two right now, but there's probably 80 in clinical pipelines right now globally. We have 11 others, but there's probably 70 others not coming from Lilly.”
Ricks: Drugs lose 97% of their pricing when patents expire
“Typically a generic event, you'll lose 97% of your pricing the day your patent expires.”
Ricks: PBM rebate incentives should be eliminated as unethical
“These PBMs and there's some group purchasing organizations like this. That should go away. And I think health is different than other commodities. It's probably has a much more important social role in deciding that the smallest, the little guy gets the worst …”
Ricks: Lilly's net insulin price stayed near $30 despite $275 list price
“Our actual net on insulin really hasn't changed. It's like 30 or 40 dollars, but the list price got up to two 75.”
Ricks: Insurers initially refused to cover Eli Lilly's discounted generic insulin
“In the first year, no formularies covered this. So it was really only for that cash payer. No insurance company picked it up, even though it was dramatically cheaper. Now it's about half of the volume, but still half not because that model of this margin sprea…”
Ricks: Early-stage biotechs pitch 80% to 100% of revenue from the US
“If you fund, if you went out and said, hey, I want to back some biotechs, and they sent you their business plan, 80 to a hundred percent of the revenue in return they'll pitch you on is the US. Meaning there is no return outside the US if you start at the poin…”
Ricks: Most major hospital systems have failed price transparency compliance
“Compliance is terrible. Most major hospital systems have not complied. Or if they have, they put on a website somewhere a coded database that is impossible to interpret with ICD-X codes and price points that consumers cannot digest.”
Ricks: The US and China hold 70% of global diagnostic capacity
“The US and China have something like 70% of all diagnostic capacity in the world.”
Ricks: Over half of approved drugs originate in biotech, but few finish
“While it's true that the origin of, I think it's a little more than half of medicines approved in the last 10 years have come from biotech, hardly any of those traveled all the way through biotech.”
Ricks: Lilly conducts early clinical trials faster and cheaper than any biotech
“There is no doubt in my mind. We are faster, more robust, probably cheaper than actually every biotech out there trying to do their own early phase clinical trials.”
Ricks: Lilly's 400-person San Diego hub produced one-third of its medicines
“We built a monoclonal antibody biotech hub there. It's produced like a third of the medicines we've made since we started. Hugely successful. There's 400 employees.”
Ricks: 80% of effective COVID treatments were produced in US
“Basically, 80% of the medicines and vaccines that worked were produced in the United States.”
Ricks: China had Pfizer-BioNTech vaccine rights but never approved it
“They had rights to the BioNTech-Pfizer vaccine for almost the entirety of their pandemic. They never approved it.”
Collison: India's largest generic manufacturer paid a $500M fraud fine
“The largest generic manufacturer in India, I forget its name paid a half a billion dollar fine in 2013. Yeah, for rampant fraud and falsification and abuse of the biosimilarity analyses and so forth”
Ricks: Virtually no generic pharmaceuticals are manufactured in the US
“There are no generics manufactured in the U.S. Really.”
Ricks: Generic small-molecule medicines face no regulatory efficacy requirement
“There is no requirement For small molecule chemical medicine to show proof of efficacy of any kind. So you can do pretty simple laboratory experiments and absorption experiments in a small number of people.”
Ricks: Healthcare systems should pay a premium for generic drug resilience
“And we probably should pay a little bit more for generics. You sometimes read about injectable generics in particular that run short. That's a more complicated manufacturing process. So if you do it cheaply, you run into more problems. We probably should pay a…”
Ricks: Eli Lilly's chronic knee pain study is going to work
“We have a study reading out toward the end of this year in chronic knee pain. It's going to work.”
Ricks: Taltz plus Zepbound trial is certain to boost psoriasis efficacy
“So we're doing a study with our psoriasis drug, Taltz, and ZepBound. That will read out this fall. And I'm certain we'll show a boost in efficacy with the weight loss.”
Ricks: Self-pay Zepbound is the #1 prescribed form of GLP-1s
“Actually, the number one prescribed form of these medications is Zep-bound self-buy. We sell more than that than our insured business, a new patient starts, and more than all of we go.”
Ricks: 70% of Eli Lilly's ad budget is off linear TV
“70% of our spend now is not on linear TV. So most of the advertising is more served up and in your search sequence, and increasingly we're interested in like, generative AI optimization.”
Ricks: Marketing halves medical adoption time from 16 to eight years
“And there's been studies on this of medical inventions that are not promoted... It's about a sixteen-year path to full adoption. With the medicine promoted, it's half that. We have an internal goal to half that again, to get to four years, to full whatever it …”
Ricks: LillyDirect annualizes in billions as largest online prescription platform
“Today we'll annualize, you know, in the billions of dollars. I think it's the largest Prescription platform online in terms of revenue. We run it on Stripe, I think, and going north from here.”
Ricks: Tirzepatide's US patent extends into the late 2030s
“I think Terseptide's U.S. Patent is late thirties or foregrip on the oral beyond that.”
Ricks: Eli Lilly captures 70-75% of new US GLP-1 starts
“Right now in the US, across all forms of GLP-ONE, on new patient capture, we're basically 70, 75% right now.”
Ricks: Extending human lifespans inherently increases total disease burden
“You know, there's no limit to human disease, and actually the longer we help people live, the more disease they'll be.”
Ricks: Pharma must invest 20-25% of revenue in R&D for double-digit growth
“I have a belief that if you're not generating, to generate double digit growth in the sector, you need to invest at 20 to 25% of sales in R&D. That's sort of a good, a positive return R&D stack.”
Ricks: Lilly has small molecule and siRNA Lp(a) drugs in Phase 3
“Like we talked about LP a earlier. That was the case there. We discarded the antibody. There is one that's been developed. And we went after the small molecule and the siRNA. They're both in phase three.”
Ricks: Lilly has had 11 CEOs in 150 years, only one external
“We've had a 150 years of that, and I'm the 11th CEO of the company. That's one less than Pope's in that period of time. So that's, it was a special honor, actually, and it's not a lifetime appointment. I can be fired any day, but the first four were family mem…”